300199 翰宇药业
已收盘 07-22 15:00:00
资讯
新帖
简况
最高减重20%！礼来“替尔泊肽”在华获批，效果强过司美格鲁肽？
格隆汇 · 07-22 10:20
最高减重20%！礼来“替尔泊肽”在华获批，效果强过司美格鲁肽？
翰宇药业(300199.SZ)子公司通过复评换发工业大麻加工许可证
智通财经 · 07-18
翰宇药业(300199.SZ)子公司通过复评换发工业大麻加工许可证
翰宇药业(300199.SZ)：注射用特利加压素获智利批准证书
智通财经 · 07-04
翰宇药业(300199.SZ)：注射用特利加压素获智利批准证书
翰宇药业(300199.SZ)：鲑降钙素原料药获上市申请批准
智通财经 · 07-01
翰宇药业(300199.SZ)：鲑降钙素原料药获上市申请批准
翰宇药业(300199.SZ)：替尔泊肽原料药获得美国DMF备案号
智通财经 · 06-27
翰宇药业(300199.SZ)：替尔泊肽原料药获得美国DMF备案号
翰宇药业（300199）6月25日主力资金净买入1524.15万元
证券之星 · 06-26
翰宇药业（300199）6月25日主力资金净买入1524.15万元
更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥，A股概念股逆市上扬
Reuters · 06-25
更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥，A股概念股逆市上扬
翰宇药业(300199.SZ)：利拉鲁肽注射液获得美国FDA暂定批准
智通财经 · 06-24
翰宇药业(300199.SZ)：利拉鲁肽注射液获得美国FDA暂定批准
翰宇药业：拟向上海银行申请不超2亿元综合授信额度
每日经济新闻 · 06-13
翰宇药业：拟向上海银行申请不超2亿元综合授信额度
翰宇药业（300199）6月7日主力资金净买入3211.43万元
证券之星 · 06-11
翰宇药业（300199）6月7日主力资金净买入3211.43万元
翰宇药业利拉鲁肽注射液首次出口美国 与碧迪医疗达成战略合作
证券时报网 · 06-07
翰宇药业利拉鲁肽注射液首次出口美国 与碧迪医疗达成战略合作
减肥药概念午后异动 翰宇药业大涨10%
市场资讯 · 06-07
减肥药概念午后异动 翰宇药业大涨10%
翰宇药业两年亏8.85亿营收连降 深耕减肥药频获海外大单难解压
市场资讯 · 06-04
翰宇药业两年亏8.85亿营收连降 深耕减肥药频获海外大单难解压
翰宇药业（300199）5月29日主力资金净卖出7885.96万元
证券之星 · 05-30
翰宇药业（300199）5月29日主力资金净卖出7885.96万元
翰宇药业牵手三生制药：司美格鲁肽能否成为新盈利点
21世纪经济报道 · 05-29
翰宇药业牵手三生制药：司美格鲁肽能否成为新盈利点
翰宇药业：今日，翰宇药业与三生蔓迪就司美格鲁肽注射液（减重适应症）签署合作协议
证券之星 · 05-28
翰宇药业：今日，翰宇药业与三生蔓迪就司美格鲁肽注射液（减重适应症）签署合作协议
翰宇药业与三生蔓迪达成合作 开拓司美格鲁肽市场机会
证券时报网 · 05-28
翰宇药业与三生蔓迪达成合作 开拓司美格鲁肽市场机会
翰宇药业(300199.SZ)与三生蔓迪签订《司美格鲁肽注射液合作协议》
智通财经 · 05-28
翰宇药业(300199.SZ)与三生蔓迪签订《司美格鲁肽注射液合作协议》
三生制药(01530)：三生蔓迪与翰宇药业就司美格鲁肽注射液达成合作协议
智通财经 · 05-28
三生制药(01530)：三生蔓迪与翰宇药业就司美格鲁肽注射液达成合作协议
翰宇药业(300199.SZ)：醋酸加尼瑞克注射液获批上市
智通财经 · 05-27
翰宇药业(300199.SZ)：醋酸加尼瑞克注射液获批上市
加载更多
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业，主要产品包括多肽制剂药品、多肽原料药、客户定制肽、美容肽、固体制剂药品、医疗器械、多肽护肤品、大健康类产品等多个系列。公司上榜2023年广东制造业企业500强，并获得深圳市“专精特新”企业认定；翰宇武汉公司荣膺黄陂区“优秀先进制造业企业”，再次凸显公司高水准的质量优势。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":9.76,"timestamp":1721631810000,"preClose":9.65,"halted":0,"volume":12628213,"delay":0,"floatShares":666000000,"shares":883000000,"eps":-0.6189,"marketStatus":"已收盘","marketStatusCode":5,"change":0.11,"latestTime":"07-22 15:00:00","open":9.66,"high":9.86,"low":9.5,"amount":123000000,"amplitude":0.0373,"askPrice":9.77,"askSize":338,"bidPrice":9.76,"bidSize":2666,"shortable":0,"etf":0,"ttmEps":-0.6189,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":9.65,"symbolType":"stock","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":10.62,"lowLimit":8.69,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"pbRate":11.4,"roa":"--","roe":"--","epsLYR":-0.58,"committee":-0.086587,"marketValue":8620000000,"floatMarketCap":6500000000,"peRate":-15.769914,"changeRate":0.0114,"turnoverRate":0.019,"status":0},"requestUrl":"/m/hq/s/300199","defaultTab":"news","newsList":[{"id":"2453786850","title":"最高减重20%！礼来“替尔泊肽”在华获批，效果强过司美格鲁肽？","url":"https://stock-news.laohu8.com/highlight/detail?id=2453786850","media":"格隆汇","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453786850?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:20","pubTimestamp":1721614814,"startTime":"0","endTime":"0","summary":"竞争白热化？","market":"us","thumbnail":"https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/869192","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4534","LU1551013342.USD","LU1623119135.USD","LU2328871848.SGD","LU0122379950.USD","NVO","LU0256863811.USD","300199","603087","IE00BJT1NW94.SGD","BK4532","LU0096364046.USD","LU1551013425.SGD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU0471298694.HKD","BK0183","LU0097036916.USD","LU0385154629.USD","000963","BK0187","BK0239","LU0061475181.USD","IE0002141913.USD","LU0109391861.USD","LU1804176565.USD","LI","BK4533","BK4516","LU0708995401.HKD","LU1280957306.USD","BK0188","LU0943347566.SGD","IE00BJLML261.HKD","IE00B1BXHZ80.USD","LU1061106388.HKD","BK0077","GB00BDT5M118.USD","IE0009355771.USD","LU0820561909.HKD","LU0114720955.EUR","BK0175","BK4007","LU1093756168.USD","LU0079474960.USD","LU1035775433.USD","LU0882574055.USD","LU0058720904.USD","LU0094547139.USD","IE0004445239.USD"],"gpt_icon":1},{"id":"2452725151","title":"翰宇药业(300199.SZ)子公司通过复评换发工业大麻加工许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2452725151","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452725151?lang=zh_cn&edition=full","pubTime":"2024-07-18 16:45","pubTimestamp":1721292349,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，2022年7月22日，公司控股子公司翰宇生物科技(大理)有限公司(“翰宇大理”)收到云南省大理市公安局核发的《云南省工业大麻加工许可证》(批准号：云南省大理市麻加准字1号)，有效期限自2022年7月21日至2024年7月20日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","300199","BK0188","BK0239","BK0070","BK0077"],"gpt_icon":0},{"id":"2448414501","title":"翰宇药业(300199.SZ)：注射用特利加压素获智利批准证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448414501","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448414501?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:30","pubTimestamp":1720081810,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)公告，公司收到智利国家药品管理局颁发的关于注射用特利加压素的批准证书。注射用特利加压素的适应症为：治疗食管静脉曲张出血。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0239","300199","BK0028","BK0188","BK0077"],"gpt_icon":0},{"id":"2448965307","title":"翰宇药业(300199.SZ)：鲑降钙素原料药获上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2448965307","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448965307?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:24","pubTimestamp":1719822288,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)公告，公司全资子公司翰宇药业(武汉)有限公司(简称“翰宇武汉”)收到国家药品监督管理局签发的关于鲑降钙素原料药《化学原料药上市申请批准通知书》。 公告显示，鲑降钙素是调节钙代谢，抑制甲状旁腺的激素之一，它能显著地降低高周转性骨病的骨钙丢失，诸如骨质疏松症、变形性骨病、痛性神经营养不良症和恶性骨质溶解症，对停经后骨质疏松症的躯干骨作用比四肢骨更显著，对高周转性骨病比低转性骨病更显著。鲑降钙素能抑制破骨细胞活性，同时刺激成骨细胞形成及其活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","BK0077","300199","BK0188","BK0070"],"gpt_icon":0},{"id":"2446536028","title":"翰宇药业(300199.SZ)：替尔泊肽原料药获得美国DMF备案号","url":"https://stock-news.laohu8.com/highlight/detail?id=2446536028","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446536028?lang=zh_cn&edition=full","pubTime":"2024-06-27 20:02","pubTimestamp":1719489729,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，2024年6月27日，公司收到美国食品药品监督管理局(FDA)的确认，已收到提交的替尔泊肽Drug master file(DMF)。根据美国的联邦管理法规定，药品进入美国须向美国FDA申请注册并递交有关文件，化学原料药按要求提交一份药物管理档案(DMF)。DMF是一套有关产品生产和质量控制方面的文件资料，主要包括生产商的成品质量标准和检验方法、生产工艺描述、物料控制、杂质控制、稳定性以及其它质量控制方面的内容。在同品种的市场竞争中，取得DMF注册登记号的企业和其产品容易被客户优先考虑，有利于企业寻找市场机遇、开拓客户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["DMF","BK0188","300199","BK0077","BK0239","BK0028","BK0070"],"gpt_icon":0},{"id":"2446802124","title":"翰宇药业（300199）6月25日主力资金净买入1524.15万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446802124","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446802124?lang=zh_cn&edition=full","pubTime":"2024-06-26 09:12","pubTimestamp":1719364340,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月25日收盘，翰宇药业报收于11.33元，上涨5.2%，换手率6.24%，成交量41.57万手，成交额4.61亿元。近5日资金流向一览见下表：翰宇药业融资融券信息显示，融资方面，当日融资买入4571.53万元，融资偿还4066.31万元，融资净买入505.22万元。翰宇药业主营业务：特色原料药、注射剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600013550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0070","BK0239","BK0188","BK0077","300199"],"gpt_icon":0},{"id":"2446471897","title":"更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥，A股概念股逆市上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2446471897","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446471897?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:39","pubTimestamp":1719308396,"startTime":"0","endTime":"0","summary":" 路透上海6月25日 - 丹麦诺和诺德 的司美格鲁肽号称“减肥神药”，在爱美人士中走红。现在这款药物终于在中国原研专利到期前，被批准用于治疗超重和肥胖症。这意味着中国也成为继日本之后，第二个批准诺和诺德的司美格鲁肽治疗肥胖的亚洲国家。诺和诺德大中国区高管在3月表示，在中国推出的用于减肥的司美格鲁肽最开始将以自费患者为主。诺和诺德的司美格鲁肽在中国的专利将于2026年3月20日到期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","300199","BK0183","BK4534","IE0002141913.USD","LU1988902786.USD","LU1551013342.USD","LU2491049909.HKD","LU1804176565.USD","LU2148510915.USD","IE0004445239.USD","LU0882574055.USD","LU0122379950.USD","GB00BDT5M118.USD","01801","LU2237438978.USD","LU2264538146.SGD","LU1064130708.USD","LLY","LU1280957306.USD","LU1814569148.SGD","399300","LU1057294990.SGD","LU0289739699.SGD","BK4533","BK0077","BK4007","LU0109391861.USD","LU2468319806.SGD","LU0672654240.SGD","BK0070","159982","000963","BK0175","IE00B1BXHZ80.USD","BK0239","LU1551013425.SGD","BK1589","LU1023059063.AUD","300122","LU0256863811.USD","LU0417517546.SGD","LU0058720904.USD","LU0708995401.HKD","LU2491050071.SGD","IE00BJT1NW94.SGD","LU0079474960.USD","LU0061475181.USD","IE00BJJMRZ35.SGD","03692"],"gpt_icon":0},{"id":"2445604721","title":"翰宇药业(300199.SZ)：利拉鲁肽注射液获得美国FDA暂定批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2445604721","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445604721?lang=zh_cn&edition=full","pubTime":"2024-06-24 16:38","pubTimestamp":1719218312,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业 发布公告，公司收到美国食品药品监督管理局的通知，由翰宇药业及Hikma Pharmaceuticals USA,Inc.联合向FDA申报的利拉鲁肽注射液新药简略申请已获得暂定批准。据悉，暂定批准指FDA已经完成仿制药的所有审评要求，即药品经审查，质量、安全和有效性已符合在美国上市的标准，出于专利权和/或独占权未到期的原因，而给予的一种批准形式。直至专利或独占权问题解决后，美国FDA才能给予在美国终端市场销售的资格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0188","BK0070","300199","BK0077"],"gpt_icon":0},{"id":"2443574740","title":"翰宇药业：拟向上海银行申请不超2亿元综合授信额度","url":"https://stock-news.laohu8.com/highlight/detail?id=2443574740","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443574740?lang=zh_cn&edition=full","pubTime":"2024-06-13 16:59","pubTimestamp":1718269140,"startTime":"0","endTime":"0","summary":"6月13日，翰宇药业公告，为进一步拓展融资渠道、优化财务结构、补充公司流动资金，保证公司发展需求，同意公司向上海银行股份有限公司深圳分行申请额度不超过2亿元人民币的综合授信额度，授信期限暂定为3年，本次融资授信担保方式及授信额度与期限以银行实际审批为准。（文章来源：每日经济新闻）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061317022595ac0ed9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061317022595ac0ed9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0183","SGXZ81163826.USD","BK0278","300199","BK0077","BK0070","SGXZ49509284.SGD","BK0187","BK0188","BK0028","BK0020","601229"],"gpt_icon":0},{"id":"2442801774","title":"翰宇药业（300199）6月7日主力资金净买入3211.43万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442801774","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442801774?lang=zh_cn&edition=full","pubTime":"2024-06-11 09:11","pubTimestamp":1718068300,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月7日收盘，翰宇药业报收于10.6元，上涨8.05%，换手率5.52%，成交量36.76万手，成交额3.82亿元。近5日资金流向一览见下表：翰宇药业融资融券信息显示，融资方面，当日融资买入2367.49万元，融资偿还2822.48万元，融资净偿还454.99万元。翰宇药业主营业务：特色原料药、注射剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100002036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","BK0070","300199","BK0077"],"gpt_icon":0},{"id":"2441053914","title":"翰宇药业利拉鲁肽注射液首次出口美国 与碧迪医疗达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2441053914","media":"证券时报网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441053914?lang=zh_cn&edition=full","pubTime":"2024-06-07 18:07","pubTimestamp":1717754855,"startTime":"0","endTime":"0","summary":"6月7日，翰宇药业(300199)利拉鲁肽注射液首次出口美国发车仪式在翰宇药业坪山制剂生产基地启幕，首批产品正式发往美国市常同日，翰宇药业与碧迪医疗器械（上海）有限公司（简称“碧迪医疗” ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20240607/c658656549.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20240607/c658656549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","BK0028","300199","BK0077","BK0070","BK0188"],"gpt_icon":0},{"id":"2441089103","title":"减肥药概念午后异动 翰宇药业大涨10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441089103","media":"市场资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441089103?lang=zh_cn&edition=full","pubTime":"2024-06-07 13:16","pubTimestamp":1717737360,"startTime":"0","endTime":"0","summary":"专题：当前基本面仍未进入右侧 机构预计市场仍将保持震荡格局\n 6月7日消息，减肥药概念午后异动，翰宇药业大涨10%，常山药业、康惠制药（维权）、科源制药、睿智医药等跟涨。\n 消息面上，2024年美国糖尿病协会（ADA）第84届年会将于6月21-24日在美国奥兰多召开。世界肥胖联盟预测全球超重或肥胖人数将由2020年26亿增加至2035年40亿。中信证券预计到2030年我国减肥用GLP-1受体激动剂的市场规模将达到383亿元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：王其霖","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/2024-06-07/doc-inaxwtaf5351058.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/2024-06-07/doc-inaxwtaf5351058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","300199","BK0188","BK0239","BK0070","BK0077"],"gpt_icon":0},{"id":"2440409264","title":"翰宇药业两年亏8.85亿营收连降 深耕减肥药频获海外大单难解压","url":"https://stock-news.laohu8.com/highlight/detail?id=2440409264","media":"市场资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440409264?lang=zh_cn&edition=full","pubTime":"2024-06-04 07:45","pubTimestamp":1717458300,"startTime":"0","endTime":"0","summary":" 专注多肽类药物的翰宇药业在减重领域再进一步。 近日，翰宇药业发布公告称，公司与浙江三生蔓迪药业有限公司签署《司美格鲁肽注射液合作协议》，三生蔓迪将向翰宇药业支付最高2.7亿元的里程碑付款。 长江商报记者注意到，翰宇药业业绩承压，近两年，公司营收连降，归母净利润累计亏损8.85亿元。 减肥减重药风口正盛，翰宇药业持续深耕这一领域。截至2024年一季度末，翰宇药业的负债率为74.11%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-06-04/doc-inaxpkzq3966614.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-06-04/doc-inaxpkzq3966614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300199"],"gpt_icon":0},{"id":"2439463710","title":"翰宇药业（300199）5月29日主力资金净卖出7885.96万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439463710","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439463710?lang=zh_cn&edition=full","pubTime":"2024-05-30 09:19","pubTimestamp":1717031988,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月29日收盘，翰宇药业报收于12.29元，下跌3.08%，换手率5.16%，成交量34.39万手，成交额4.3亿元。近5日资金流向一览见下表：翰宇药业融资融券信息显示，融资方面，当日融资买入4068.09万元，融资偿还5476.8万元，融资净偿还1408.7万元。翰宇药业主营业务：特色原料药、注射剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053000012622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300199","BK0077","BK0028","BK0070","BK0239"],"gpt_icon":0},{"id":"2439552210","title":"翰宇药业牵手三生制药：司美格鲁肽能否成为新盈利点","url":"https://stock-news.laohu8.com/highlight/detail?id=2439552210","media":"21世纪经济报道","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439552210?lang=zh_cn&edition=full","pubTime":"2024-05-29 20:48","pubTimestamp":1716986904,"startTime":"0","endTime":"0","summary":"21 世纪经济报道记者 杨坪 深圳报道翰宇药业（300199.SZ）与三生制药（1530.HK）的合作，在行业引发遐想。5 月 28 日晚间，翰宇药业发布公告，审议通过了《关于与合作方签署司美格鲁肽注射 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20240529/c658337659.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20240529/c658337659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","BK0028","300199","BK0077","BK0070","BK0188"],"gpt_icon":0},{"id":"2438370218","title":"翰宇药业：今日，翰宇药业与三生蔓迪就司美格鲁肽注射液（减重适应症）签署合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2438370218","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438370218?lang=zh_cn&edition=full","pubTime":"2024-05-28 22:00","pubTimestamp":1716904832,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业05月28日在投资者关系平台上答复投资者关心的问题。按协议约定，三生蔓迪将向翰宇药业支付：里程碑付款、独家采购价、以及约两位数销售提成。双方以中国为首开展合作布局，翰宇药业多肽药物研发及国际标准产品质量，与三生蔓迪在大健康领域线上线下的渠道实力强强联合，协同效应显著。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052800039583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0070","BK0239","300199","BK0077"],"gpt_icon":0},{"id":"2438969371","title":"翰宇药业与三生蔓迪达成合作 开拓司美格鲁肽市场机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2438969371","media":"证券时报网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438969371?lang=zh_cn&edition=full","pubTime":"2024-05-28 20:39","pubTimestamp":1716899977,"startTime":"0","endTime":"0","summary":"5月28日晚间翰宇药业(300199)公告，与三生蔓迪就司美格鲁肽注射液（减重适应症）签署合作协议，双方将围绕该产品药物开发、临床研究、注册申报、大健康渠道以及品牌打造等环节进行协同，三 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20240528/c658290412.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20240528/c658290412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["300199","BK0239","BK0077","BK0070","BK0028","BK0188"],"gpt_icon":0},{"id":"2438378052","title":"翰宇药业(300199.SZ)与三生蔓迪签订《司美格鲁肽注射液合作协议》","url":"https://stock-news.laohu8.com/highlight/detail?id=2438378052","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438378052?lang=zh_cn&edition=full","pubTime":"2024-05-28 20:02","pubTimestamp":1716897748,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)公告，公司与浙江三生蔓迪药业有限公司(“三生蔓迪”)签署《司美格鲁肽注射液合作协议》，公司将与三生蔓迪共同合作开发、独家供应/采购、销售分成司美格鲁肽注射液(减重适应症)，三生蔓迪将根据协议约定向翰宇药业支付：里程碑付款(最高人民币2.7亿元)、独家采购价、以及约两位数销售提成。据悉，本次合作有利于加快公司推进司美格鲁肽研发的进一步布局，实现研发成果的加速转化，通过充分发挥双方在产品开发和商业化的优势，完成互惠互利的合作，使司美格鲁肽注射液(减重适应症)在塑造品牌影响力的同时，线上和线下渠道快速铺开，从而提升公司的核心竞争力，增加公司的盈利点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1127279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0028","300199","BK0077","BK0070"],"gpt_icon":0},{"id":"2438324565","title":"三生制药(01530)：三生蔓迪与翰宇药业就司美格鲁肽注射液达成合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2438324565","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438324565?lang=zh_cn&edition=full","pubTime":"2024-05-28 18:50","pubTimestamp":1716893426,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药 发布公告，该公司的附属公司沈阳三生制药有限责任公司的全资附属公司浙江三生蔓迪药业有限公司与深圳翰宇药业股份有限公司签署《司美格鲁肽注射液合作协议》。三生蔓迪将根据协议约定向翰宇药业支付最高人民币2.7亿元里程碑付款，其中包含人民币4500万元的临床前技术成果对价款;此外，三生蔓迪还将向翰宇药业支付独家采购价以及销售提成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1127177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","01530","BK0077","BK0188","BK0239","BK0028","BK1583","BK1593","BK1161","300199"],"gpt_icon":0},{"id":"2438877320","title":"翰宇药业(300199.SZ)：醋酸加尼瑞克注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2438877320","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438877320?lang=zh_cn&edition=full","pubTime":"2024-05-27 15:50","pubTimestamp":1716796220,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)公告，公司收到国家药品监督管理局下发的《药品注册证书》(受理号：CYHS2201612)，公司“醋酸加尼瑞克注射液”获得药品注册批准。据悉，醋酸加尼瑞克注射液在接受辅助生殖技术(ART)控制性卵巢刺激(COS)方案的妇女中使用，用于预防过早出现促黄体激素(LH)峰。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126405.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0070","300199","BK0077","BK0028","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","stockEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.1665},{"period":"3month","weight":-0.202},{"period":"6month","weight":-0.1658},{"period":"1year","weight":-0.0441},{"period":"ytd","weight":-0.2813}],"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","perCapita":"9231股","boardName":"医药制造业","registeredCapital":"88324万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业，主要产品包括多肽制剂药品、多肽原料药、客户定制肽、美容肽、固体制剂药品、医疗器械、多肽护肤品、大健康类产品等多个系列。公司上榜2023年广东制造业企业500强，并获得深圳市“专精特新”企业认定；翰宇武汉公司荣膺黄陂区“优秀先进制造业企业”，再次凸显公司高水准的质量优势。","serverTime":1721672318267,"listedPrice":30.19,"stockholders":"72151人(较上一季度减少4.89%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}